# US 11,992,511 B2 · Lactobacillus paracasei strain and use thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,992,511 B2 - Document ID: US11992511B2 - Status: Granted - Kind: B2 - Application number: 17/673,460 - Filed: 2022-02-16 - Published: 2022-06-09 - Granted: 2024-05-28 - Earliest claimed: 2018-05-09 - Assignees: Kobiolabs, Inc. - Applicants: KoBioLabs, Inc. - Inventors: Gwang Pyo Ko; Woonki Kim; You-Jin Jang; Boram Seo; June-Chul Lee; Tae-Wook Nam; Insu Kim; Jin-Woo Lee - Web page: https://patentgrep.com/patent/US11992511B2 ## CPC - A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis - A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection - A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics - A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula} - A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system - A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) - C12N 1/20: Bacteria; Culture media therefor - C12N 1/205: Bacterial isolates - A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs - A23V 2400/165: Paracasei - A61K 2035/115: {Probiotics} - C12R 2001/225: Lactobacillus - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION - C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS ## Abstract Human-derived probiotic strains Lactobacillus paracasei KBL382, Lactobacillus paracasei KBL384 and Lactobacillus paracasei KBL385 are described, as well as uses of the strains for improving intestinal health and treating or preventing intestinal diseases. The strains have excellent anti-inflammatory and immunomodulatory functions, superb strengthening effects on tight junctions of the intestinal tract wall, suppress enteritis-induced weight loss and colon length reduction, thereby exhibiting therapeutic effects for enteritis, and significantly alleviate the symptoms of atopic dermatitis. The strains can be used as probiotic material for enhancing anti-inflammatory effects, strengthening immunity, improving intestinal health functions, and alleviating allergic diseases. ## Claims ### Claim 1 A composition in a dry dosage form of capsule, tablet, or powder, comprising: at least one lyophilized strain of Lactobacillus paracasei selected from Lactobacillus paracasei KBL384 with Accession No. KCTC13510BP, Lactobacillus paracasei KBL385 with Accession No. KCTC13511BP, or lyophilized cultures of said strain. ### Claim 2 (depends on 1) The composition according to claim 1, wherein strain KBL384 comprises 16s rDNA sequence of SEQ ID NO: 2. ### Claim 3 (depends on 1) The composition according to claim 1, wherein strain KBL385 comprises 16s rDNA sequence of SEQ ID NO: 3. ### Claim 4 (depends on 1) The composition according to claim 1, wherein the composition is a food composition. ### Claim 5 (depends on 4) The composition according to claim 4, wherein said food composition is a health functional food composition for improvement of intestinal health. ### Claim 6 (depends on 4) The composition according to claim 4, wherein said food composition is a health functional food composition for improving allergic symptoms. ### Claim 7 (depends on 4) The composition according to claim 4 wherein said food composition is a health functional food composition for alleviating autoimmune disease or inflammatory disease. ### Claim 8 (depends on 1) The composition according to claim 1, wherein the composition is a food additive composition. ### Claim 9 (depends on 1) The composition according to claim 1, wherein the composition is a pharmaceutical composition for the treatment or prevention of intestinal disease. ### Claim 10 (depends on 9) The composition according to claim 9, wherein said intestinal disease is selected from abdominal bloating, abdominal discomfort, infectious diarrhea caused by pathogenic microorganisms, gastroenteritis, inflammatory bowel diseases, neurogenical intestinitis syndrome, irritable bowel syndrome, overgrowth of small intestinal microorganisms and intestinal feeding diarrhea. ### Claim 11 (depends on 1) The composition according to claim 1, wherein the composition is a pharmaceutical composition for the treatment or prevention of allergic disease. ### Claim 12 (depends on 11) The composition according to claim 11, wherein said allergic disease is atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, asthma, food allergy or anaphylactic shock. ### Claim 13 (depends on 1) The composition according to claim 1, wherein the composition is a pharmaceutical composition for the treatment or prevention of autoimmune disease. ### Claim 14 (depends on 1) The composition according to claim 1, wherein the composition is a pharmaceutical composition for the treatment or prevention of inflammatory disease. ### Claim 15 (depends on 1) A method for treating, alleviating or preventing intestinal disease, allergic disease, autoimmune disease or inflammatory disease comprising administering a therapeutically effective amount the composition according to claim 1. ### Claim 16 A composition in a dry dosage form of capsule, tablet, or powder, comprising: at least one lyophilized strain of Lactobacillus paracasei KBL384 with Accession No. KCTC13510BP, Lactobacillus paracasei KBL385 with Accession No. KCTC13511BP, or lyophilized cultures of said strain, and a pharmaceutically acceptable excipient, diluent, or carrier. ### Claim 17 (depends on 16) The composition according to claim 16, wherein the composition is in solid form.